

Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/HDA61EDB0DABEN.html>

Date: February 2022

Pages: 59

Price: US\$ 2,000.00 (Single User License)

ID: HDA61EDB0DABEN

Abstracts

Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape.

Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness, or confusion, change in sleep patterns, slurred speech and agitation, excitement, or seizures (occur rarely). The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation (due to increased nitrogen load), drugs (particularly sedatives and diuretics) and hypoxia.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive

pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 4 and 3 respectively.

Hepatic Encephalopathy (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hepatic Encephalopathy

(Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hepatic Encephalopathy (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hepatic Encephalopathy (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hepatic Encephalopathy (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Hepatic Encephalopathy - Overview
- Hepatic Encephalopathy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Hepatic Encephalopathy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hepatic Encephalopathy - Companies Involved in Therapeutics Development
- Alfasigma SpA
- Axcella Health Inc
- Cosmo Pharmaceuticals NV
- Grifols SA
- Kaleido Biosciences Inc
- Neuropathix Inc
- Rebiotix Inc
- Takeda Pharmaceutical Co Ltd
- TenNor Therapeutics Ltd
- Umecrine Cognition AB
- Vedanta Biosciences Inc
- Versantis AG
- Hepatic Encephalopathy - Drug Profiles
- albumin (human) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AXA-1665 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- golexanolone - Drug Profile
- Product Description
- Mechanism Of Action

History of Events
KB-174 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KLS-13019 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KLS-13023 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBX-2660 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBX-7455 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rifamycin sodium CR - Drug Profile
Product Description
Mechanism Of Action
History of Events
rifaximin - Drug Profile
Product Description
Mechanism Of Action
History of Events
rifaximin SSD - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-039 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TNP-2092 - Drug Profile
Product Description

Mechanism Of Action

History of Events

VE-303 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VS-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VS-02 - Drug Profile

Product Description

Mechanism Of Action

Hepatic Encephalopathy - Dormant Projects

Hepatic Encephalopathy - Discontinued Products

Hepatic Encephalopathy - Product Development Milestones

Featured News & Press Releases

Jan 18, 2022: Neuropathix receives patent grant from India for its novel anti-inflammatory compounds

Jan 11, 2022: Karolinska Development's portfolio company Umecrine Cognition presents preclinical data showing that golexanolone reduces neuroinflammation and counteracts motor symptoms

Nov 02, 2021: Axcella Therapeutics announces upcoming presentation of AXA1665 at AASLD's The Liver Meeting 2021

Jul 14, 2021: Karolinska Development's portfolio company Umecrine Cognition raises capital through a successful share issue

Jun 30, 2021: Axcella announces initiation of EMMPOWER phase 2 clinical trial of AXA1665

May 24, 2021: Positive clinical data about Axcella's AXA1665 candidate for overt hepatic encephalopathy highlighted in oral presentation at DDW 2021

Apr 22, 2021: Axcella announces upcoming oral presentation at digestive disease week (ddw) 2021

Apr 22, 2021: Karolinska Development's portfolio company Umecrine Cognition publishes clinical research results in a highly regarded journal

Dec 29, 2020: Karolinska Development increases book value of Umecrine Cognition by SEK 234 million

Oct 07, 2020: Kaleido Biosciences to present data from candidate KB174 at The Liver Meeting 2020

Oct 06, 2020: Kannalife adds to its global IP estate receiving patent grant from Canada

for its novel anti-inflammatory compounds

Sep 02, 2020: Karolinska Development's portfolio company Umeocrine Cognition presents results from clinical phase 2a study at AALSD International Liver meeting

Aug 27, 2020: Kaleido Biosciences announces presentation of data for microbiome metabolic therapy KB174 for Hepatic Encephalopathy at The Digital International Liver Congress (EASL)

Aug 25, 2020: Kannalife receives patent grants in additional European territories

Aug 05, 2020: Axcella reports positive top-line data from AXA1665-002

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hepatic Encephalopathy, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hepatic Encephalopathy - Pipeline by Alfasigma SpA, 2022

Hepatic Encephalopathy - Pipeline by Axcella Health Inc, 2022

Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals NV, 2022

Hepatic Encephalopathy - Pipeline by Grifols SA, 2022

Hepatic Encephalopathy - Pipeline by Kaleido Biosciences Inc, 2022

Hepatic Encephalopathy - Pipeline by Neuropathix Inc, 2022

Hepatic Encephalopathy - Pipeline by Rebiotix Inc, 2022

Hepatic Encephalopathy - Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Hepatic Encephalopathy - Pipeline by TenNor Therapeutics Ltd, 2022

Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, 2022

Hepatic Encephalopathy - Pipeline by Vedanta Biosciences Inc, 2022

Hepatic Encephalopathy - Pipeline by Versantis AG, 2022

Hepatic Encephalopathy - Dormant Projects, 2022

Hepatic Encephalopathy - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hepatic Encephalopathy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/HDA61EDB0DABEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HDA61EDB0DABEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

